Mesa Laboratories, Inc.
$127.93-$5.48 (-4.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $602.9M
- P/E
- -305.4x
- EV / EBITDA
- 17.9x
- Revenue
- $241.0M
- Net margin
- -0.8%
- ROCE
- 6.1%
Price chart
Technical chartScreen technicals →+78.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +2.2%
- 3M
- +7.4%
- 6M
- +23.0%
- 1Y
- +78.7%
- 5Y
- -59.0%
52-week range
Day change -$5.48 (-4.1%) from $133 to $128 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in MLAB, bought on each weekday since 2021.
News & filings
What Mesa Laboratories filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 2.0 million US dollars in fiscal 2025.
Strengths (1)
- Operating margin of 6.8% against a peer median of 1.6%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
Read moreShow less
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
- Sector
- Technology
- Shares outstanding
- 5.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $602.9M
- P/E
- -305.4x
- P/B
- 3.8x
- EV / EBITDA
- 17.9x
- EV / Sales
- 3.1x
- P/S
- 2.5x
- 52-week high
- $142.23
- 52-week low
- $70.60
Profitability
- Operating margin
- 6.8%
- Net margin
- -0.8%
- EBITDA margin
- 17.6%
- ROE
- -1.2%
- ROCE
- 6.1%
- ROIC
- 3.7%
- ROA
- -0.5%
- Asset turnover
- 0.56
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $241.0M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 11.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 9.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -99.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $42.3M
Solvency
- Current ratio
- 0.63
- Debt / Equity
- 1.14
- Debt / Assets
- 0.42
- CFO / Net profit
- -23.71
- Cash / Market cap
- 4.5%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $241.0M |
| Cost of revenue | $90.1M |
| Gross profit | $150.9M |
| Operating expenses | $134.5M |
| Research and development | $19.5M |
| Selling, general and administrative | $115.0M |
| Operating income | $16.3M |
| Interest and other | -$10.4M |
| Pretax income | $6.0M |
| Tax and other | $7.9M |
| Net income | -$2.0M |
Revenue and net profit
Revenue grew 11.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $184.3M | $1.9M |
| FY2023 | $219.1M | $930.0k |
| FY2024 | $216.2M | -$254.2M |
| FY2025 | $241.0M | -$2.0M |
Cash flows
FY2025: $46.8M from operations, $42.3M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $39.2M | $34.8M |
| FY2023 | $28.0M | $23.4M |
| FY2024 | $44.1M | $41.6M |
| FY2025 | $46.8M | $42.3M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $241.0M+11.5%1Y
- EBITDA
- $42.3M
- Net profit
- -$2.0M
- Cash from operations
- $46.8M+6.1%1Y
- Free cash flow
- $42.3M+1.8%1Y
- Revenue CAGR, 3Y
- 9.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $241.0M | $42.3M | -$2.0M | $42.3M | -1.2% | +11.5% | -99.2% |
Monthly returns
Month-by-month returns of MLAB across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $433.4M |
| Current assets | $102.7M |
| Non-current assets | $330.7M |
| Liabilities | $273.5M |
| Current liabilities | $164.0M |
| Non-current liabilities | $109.6M |
| Equity | $159.8M |
| Retained earnings | -$188.9M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Technology companies placed by value, growth and quality; MLAB highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Mesa Laboratories, Inc.MLABthis company | $602.9M | -305.4x | 3.8x | -1.2% | 17.9x |
| VTEXVTEX | $635.9M | 31.8x | 2.7x | 8.6% | 29.2x |
| Consensus Cloud Solutions, Inc.CCSI | $632.2M | 7.5x | 45.9x | 613.7% | 6.7x |
| Clearfield, Inc.CLFD | $604.6M | -75.1x | 2.4x | -3.1% | 40.0x |
| PAR Technology CorporationPAR | $598.5M | -7.1x | 0.7x | -10.2% | -34.6x |
| Grid Dynamics Holdings, Inc.GDYN | $582.9M | 60.3x | 1.1x | 1.8% | 11.1x |
| PowerFleet, Inc.AIOT | $567.4M | — | 14.7x | -11.4% | 37.9x |
| Cerence Inc.CRNC | $557.2M | — | 3.7x | -12.4% | 57.5x |
| i3 Verticals, Inc.IIIV | $554.7M | 31.0x | 1.4x | 4.6% | 11.5x |
| Peer median | — | 19.3x | 2.5x | -0.7% | 20.3x |
Year-to-date ROI
MLAB since 1 January, against earlier years.
Historical volatility
MLAB's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 2.5% |
| FY2023 | 1.5% |
| FY2024 | 1.1% |
| FY2025 | 6.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $241.0M |
| Cost of revenueCost Of Revenue | $90.1M |
| Gross profitGross Profit | $150.9M |
| Operating expensesOperating Expense | $134.5M |
| Research and developmentResearch And Development | $19.5M |
| Selling, general and administrativeSelling General And Administration | $115.0M |
| Total expensesTotal Expenses | $224.6M |
| Operating incomeOperating Income | $16.3M |
| Interest and other | |
| Pretax incomePretax Income | $6.0M |
| TaxTax Provision | $7.9M |
| Net incomeNet Income | -$2.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $433.4M |
| Current assetsCurrent Assets | $102.7M |
| Non-current assetsTotal Non Current Assets | $330.7M |
| LiabilitiesTotal Liabilities Net Minority Interest | $273.5M |
| Current liabilitiesCurrent Liabilities | $164.0M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $109.6M |
| EquityTotal Equity Gross Minority Interest | $159.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $46.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $46.8M |
| Net income, continuing operationsNet Income From Continuing Operations | -$2.0M |
| Depreciation and amortisationDepreciation And Amortization | $24.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $24.5M |
| Depreciation | $5.4M |
| Amortization cash flowAmortization Cash Flow | $19.1M |
| Amortization of intangiblesAmortization Of Intangibles | $19.1M |
| Stock-based compensationStock Based Compensation | $13.1M |
| Deferred taxDeferred Tax | -$70.0k |
| Deferred income taxDeferred Income Tax | -$70.0k |
| Operating gains and lossesOperating Gains Losses | -$2.9M |
| Asset impairmentAsset Impairment Charge | $0.00 |
| Change in working capitalChange In Working Capital | $6.9M |
| Other non-cash itemsOther Non Cash Items | $7.2M |
| Investing cash flowInvesting Cash Flow | -$4.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$4.5M |
| Capital expenditureCapital Expenditure | -$4.5M |
| Purchase of PP&EPurchase Of PPE | -$4.3M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$4.3M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | -$250.0k |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$250.0k |
| Financing cash flowFinancing Cash Flow | -$44.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$44.5M |
| Debt issuedIssuance Of Debt | $73.5M |
| Debt repaidRepayment Of Debt | -$115.8M |
| Net debt issuedNet Issuance Payments Of Debt | -$42.4M |
| Long-term debt issuedLong Term Debt Issuance | $73.5M |
| Long-term debt repaidLong Term Debt Payments | -$115.8M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$42.4M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Stock options exercisedProceeds From Stock Option Exercised | $2.6M |
| Dividends paidCash Dividends Paid | -$3.5M |
| Common dividends paidCommon Stock Dividend Paid | -$3.5M |
| Other financing chargesNet Other Financing Charges | -$1.3M |
| Change in cashChanges In Cash | -$2.2M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 131.0% |
| Cash at the start of the yearBeginning Cash Position | $28.2M |
| Cash at the end of the yearEnd Cash Position | $27.3M |
| Free cash flowFree Cash Flow | $42.3M |
| Supplemental |
Learn while you research
Academy chapters picked for Mesa Laboratories, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Growth InvestingTech & communications often trade on growth, learn the framework.7 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read